The Effect of Telenursing Interventions in Empowering Patients With COPD

Copd Clinical Trial

Official title:

The Effect of Empowerment Model-Based Telenursing Interventions in Empowering Patients With COPD

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06217718
• Other study ID #: MarmaraU-HEM-ZA-01
• Status: Recruiting
• Phase: N/A
• Start date: April 20, 2024
• Est. completion date: October 20, 2024

Study information

• Verified date: June 2024
• Source: Marmara University
• Contact: Zahide Aksoy, MSc
• Phone: +90 541 304 91 41
• Email: aksoyzahide[@]outlook.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the effect of telenursing interventions based on the empowerment model in empowering patients with COPD.

Description:

Patient empowerment is gaining importance and popularity day by day as it can be sustained through telehealth applications. The importance of using communication technologies in providing health care services has become more evident during the COVID-19 pandemic. When integrated into healthcare, technology-centric services provide continuous and easily accessible health data for patients and help facilitate self-monitoring. With tele-nursing, COPD patients can be strengthened in health literacy by teaching them how to access accurate and reliable resources. Through tele-nursing, online support groups and forums can be created among COPD patients so that patients can share their experiences with each other. In this way, social support is provided to patients who have to remain in social isolation due to their illness.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 112
• Est. completion date: October 20, 2024
• Est. primary completion date: July 20, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Having a confirmed COPD diagnosis for at least one year

• being literate,

• Having the cognitive and mental competence to answer questions,

• Being able to use a mobile phone,

• Disease symptoms are at a level that does not interfere with communication,

• Being in COPD Stage 2 and Stage 3 according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD: Global Initiative for Chronic Obstructive Lung Disease) criteria (30% = FEV1 <80% (of expected)),

Exclusion Criteria:

• The disease is in the acute exacerbation period,

• Dyspnea is at a level that prevents cooperation,

• Having sensory loss regarding vision, hearing and speech,

• Refusal to sign informed consent forms

• It is the refusal of the research to complete the data collection tools.

Related Conditions & MeSH terms

• Copd
• Empowerment
• Self Efficacy

Intervention

Other:
• Telenursing Interventions
Patient follow-up with phone calls and text messages

Locations

Country	Name	City	State
Turkey	Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital	Istanbul	Maltepe

Sponsors (2)

Lead Sponsor	Collaborator
Zahide Aksoy	The Scientific and Technological Research Council of Turkey

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	COPD Empowerment Scale	A 31-item scale that evaluates the impact of interventions on individuals with COPD.	Pre-test, Post-test (3rd month), Follow-up Test (6th month)
Secondary	Lung Function Test	A spirometri test that evaluates lung capacity. FEV1 values will increase after the intervention.	Pre-test, Post-test (3rd month), Follow-up Test (6th month)
Secondary	COPD Assesment Test	It is an eight-item test that measures the effects of COPD and deterioration in health status. CAT assessment test score; 0-10 is low 11-20 is considered medium effective, 21-30 is considered highly effective, and 31-40 is considered very high effective.	Pre-test, Post-test (3rd month), Follow-up Test (6th month)
Secondary	Number of hospital admissions due to COPD exacerbation	The number of hospital admissions due to COPD exacerbation in the experimental group will decrease.	Pre-test, Post-test (3rd month), Follow-up Test (6th month)
Secondary	Number of hospitalizations due to COPD exacerbation	The number of hospitalizations due to COPD exacerbation in the experimental group will decrease.	Pre-test, Post-test (3rd month), Follow-up Test (6th month)
Secondary	Modified Barthel Index	A scale that evaluates physical competence and independence in daily living activities. It evaluates 0-15 points with 10 items. On this scale, where the possible score varies between 0 and 100, the higher the score, the more independent the patient is from other people.	Pre-test, Post-test (3rd month), Follow-up Test (6th month)
Secondary	Modified Medical Research Council	A brief 5-item scale describing dyspnea. Scores between 0 and 1 are considered mild, and scores of 2 and above are considered moderate to severe dyspnea.	Pre-test, Post-test (3rd month), Follow-up Test (6th month)
Secondary	Inhaler Device Use Skill Scale	An observational test that measures inhaler device usage skill, with 10 usage steps explained. 1 point for correct use of each item; Incomplete or incorrect use is given 0 points.	Pre-test, Post-test (3rd month), Follow-up Test (6th month)